Clinical Trials — 2010
Andrew D. Badley, M.D.
- Early Access of MK-0518
- Cardio-Metabolic Risk Factors in HIV+ [Protocol 1]
- Kusne/ViroPharma/Maribavir versus Oral Ganciclovir for prevention of Cytomegalovirus Disease
- The effects of Nelfinavir on Immune Function
- Maraviroc Used With Optimized Background Therapy (POEM)
- Laboratory Assay Optimization
- CXCR4 Mediated Apoptosis of Primary Hepatocytes
- The Incidence, Clinical Course and Management of Sepsis in the Intensive Care Unit: A Prospective Observational Cohort Study
- Regulation of HIV-Mediated CD4 Cell Apoptosis
Leslie T. Cooper, M.D.
- Autoimmune Determinants of Human Cardiac Myosin — This is a mechanistic registry that seeks to enroll 55 patients with acute myocarditis.
- Peripartum Cardiomyopathy Registry — This is a mechanistic registry that seeks to enroll 100 patients with peripartum cardiomyopathy.
Gregory A. Poland, M.D.
- Measles — The Immunogenetics of Measles Vaccine.
- Rubella — The Immunogenetic Mechanisms of Vaccine Response.
- Smallpox — Population Genetics Analysis Program: Immunity to Vaccines/Infections.
- Chiron — A Phase II, Single-center, Oberver-blind trial of AGRIPPAL S1/MF59 vs. AGRIPPAL S1 in Elderly Subjects.
- Novavax —A Phase 2a Randomized, Double Blind Active Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Older Adults in the US and India.
Lewis R. Roberts, Ph.D.
- 09-000096 — GIDEON: Global investigation of therapeutic decision in hepatocellular carcinoma and of its treatment. An International Non-Interventional Study with Nexavar to evaluate the safety in patients with unresectable hepatocellular carcinoma.
- 707-03 — A National Registry of Patients with or at Risk for Hepatobiliary Cancers, Including Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Adenocarcinoma, and those with Normal Risk Factors.
- 08-002048 — A phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma.